Northwire Canada EditionTuesday, August 25, 2026
Sign inSubscribe
Northwire
⌕
GOLD 4697.80 +0.4% SILVER 68.59 −1.4% COPPER 6.61 +0.3% OIL 85.01 −2.4% PALLADIUM 1359.75 +0.7% NVO 0.070 +0.0% SRA 0.780 +0.0% TUK 0.020 −20.0% GWM 0.610 −4.7% MINE 0.110 +0.0% EGM 0.100 +0.0% IRO 1.11 +2.8% CBR 1.41 +2.5% CTN 0.045 +0.0% GMX 2.06 +2.0% NPR 0.700 −2.8% CGD 1.28 +8.5% CRE 0.390 +13.0% PE 0.250 +0.0% PER 0.150 +7.1% SVRS 0.540 +8.0% GOLD 4697.80 +0.4% SILVER 68.59 −1.4% COPPER 6.61 +0.3% OIL 85.01 −2.4% PALLADIUM 1359.75 +0.7% NVO 0.070 +0.0% SRA 0.780 +0.0% TUK 0.020 −20.0% GWM 0.610 −4.7% MINE 0.110 +0.0% EGM 0.100 +0.0% IRO 1.11 +2.8% CBR 1.41 +2.5% CTN 0.045 +0.0% GMX 2.06 +2.0% NPR 0.700 −2.8% CGD 1.28 +8.5% CRE 0.390 +13.0% PE 0.250 +0.0% PER 0.150 +7.1% SVRS 0.540 +8.0%
Management Routine +

COSCIENS Biopharma Inc. Announces Results of Shareholder Meeting and Appointment of Full-Time CEO

SEC deregistration cleared, permanent CEO installed, but cash runway remains tight.

By The Northwire Desk — AI Analysis Jun 18, 2026 · 08:30 CSCI · 3.24 COSCIENS BIOPHARMA INC
Executive Summary
  • Shareholders approved all proposals at the annual general and special meeting, including director re-elections and auditor re-appointment.
  • The approved corporate share capital amendment authorizes a 150-for-1 share consolidation followed immediately by a 50-for-1 share split.
  • Peter H. Puccetti has been appointed as the permanent, full-time President and CEO, transitioning from his interim tenure that began in November 2025.
  • No new financial results, guidance, or operational updates were provided in this release.
Material Impact
  • The news is Routine - Positive. The shareholder approval of the share consolidation/split and the permanent CEO appointment were fully telegraphed and expected. The +22.7% run-up into the print indicates the market had already priced in the successful deregistration and leadership continuity. The underlying facts do not change the fundamental trajectory: a leaner, non-SEC reporting company with a tight cash balance and a shrinking core business. The market reaction and underlying facts are aligned; there is no new alpha here.
CSCI · Price
Company Overview
  • COSCIENS Biopharma Inc. develops natural plant-based active ingredients and commercializes pharmaceutical/diagnostic products. It recently discontinued its German subsidiaries and the AvenActive program, pivoting to a leaner focus on active ingredients and exploring strategic opportunities. The company is transitioning to OTCQB trading and suspending SEC reporting to reduce compliance overhead.
Read the original news release →

More from COSCIENS BIOPHARMA INC

May 12, 2026 · 17:05

COSCIENS Posts Accounting Profit Amidst Cash Burn and Program Cuts

Earnings Apr 20, 2026 · 08:00

COSCIENS Biopharma Proposes Share Consolidation to Cut Reporting Costs and Exit U.S. Registry

Other Mar 25, 2026 · 17:05

COSCIENS Sheds German Subsidiaries and $11M Pension Liability as Cash Burn Outpaces Declining Revenue

Earnings Mar 05, 2026 · 17:10

COSCIENS Provides Strategic Update

Other Dec 01, 2025 · 17:05

COSCIENS Announces Exclusive Distribution Agreement with Wuzhou Drug International for Macrilen(TM) in Hainan-Guangdong-Hong Kong-Macao Greater Bay Area and Singapore

M&A / Property Nov 14, 2025 · 17:15

COSCIENS Biopharma Inc. Announces Leadership Change

Management